Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients

Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients

IntroductionCOVID-19 patients can develop autoantibodies against a variety of secreted and membrane proteins, including some expressed on lymphocytes. However, it is unclear what proportion of patients might develop anti-lymphocyte antibodies (ALAb) and what functional relevance they might have.Meth...

Full description

Bibliographic Details
Main Authors: Ainhoa Pérez-Díez, Xiangdong Liu, Stephanie Calderon, Ashlynn Bennett, Andrea Lisco, Anela Kellog, Frances Galindo, Matthew J. Memoli, Joseph M. Rocco, Brian P. Epling, Elizabeth Laidlaw, Mike C. Sneller, Maura Manion, Glenn W. Wortmann, Rita Poon, Princy Kumar, Irini Sereti
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
COVID-19
autoantibodies
complement deposition
anti-lymphocyte Ab
lymphopenia
convalescent COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1352330/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1352330/full

Similar Items